argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies ... argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies for severe autoimmune diseases. Incorporated in 2008 under Dutch law as a Societas Europaea (SE), it leverages its proprietary Immunology Innovation Program (IIP) discovery engine, combining antibody engineering technologies like the SIMPLE ANTIBODY™ platform, NHANCE™, ABDEG™, and partnerships for ENHANZE® subcutaneous delivery, with expertise from academic and scientific collaborators to translate immunology breakthroughs into novel medicines. The company has commercialized VYVGART (efgartigimod), the first approved FcRn blocker for generalized myasthenia gravis (gMG), available in intravenous and subcutaneous forms across more than 30 countries including the U.S., EU, Japan, and others, with approvals or reviews for chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP). Its deep pipeline features empasiprubart, a C2 complement inhibitor in Phase 3, alongside earlier-stage candidates like ARGX-119 (MuSK agonist) and others targeting immunology pathways in neurology, hematology, rheumatology, dermatology, and nephrology. argenx SE operates subsidiaries across Europe, North America, and Australia, emphasizing co-creation and innovation to address unmet needs in immunology.